Framingham company pens $10M Australian deal
Business Wire
Dr. Christie Hunter (SCIEX Director of OMICs Applications) visits the ProCan facility to meet with CMRI Chief Scientists and Executives and begin the implementation of the SCIEX Industrialized Proteomics solution. From left to right; Dr. Christie Hunter, Prof. Roger Reddel (Director of CMRI and Head of Cancer research Unit), Chris Hodgkins (Market Development Manager, SCIEX Oceania), Prof. Phil Robinson (Head of Cell Signaling Unit and co-developer of ProCan) and Valentina Valova (Manager of Biomedical Proteomics Facility and ProCan, CMRI).
Framingham-based SCIEX has partnered with the Australian Cancer Research Foundation International Centre to provide the organization with $10 million in equipment that will be used to investigate the cause of and treatment options for cancer.
The new Proteome of Cancer (ProCan) facility, in Westmead, Australia, will do profiling studies of thousands of tumor samples per year. It was established using $10 million in seed money that will be used to purchase SCIEX equipment, according to a release from the company.
SCIEX solutions reduce the variability associated with working with cancer samples and enables a higher sample throughput, which will help to accelerate cancer research and precision medicine at large, Chris Radloff, Global Vice President and General Manager of the LC-MS Business at SCIEX, said in a statement.
The agreement provides ProCan with the high sample throughput required for the industrialization of proteomics via a large suite of SCIEX TripleTOF® 6600 mass spectrometers and NanoLC 400 HPLCs.
WBJ Web Partners
Most Recent
Most Recent
0 Comments